Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Evolving treatment goals in CML

Susanne Saussele • 16 Apr 2018
BSH 2018
Chronic Myeloid Leukemia Leukemia

The aims of treatment for chronic myeloid leukemia (CML) have changed in recent years, as explained here by Susanne Saussele, MD, of the University of Mannheim, Mannheim, Germany. With the introduction of tyrosine kinase inhibitors, overall survival has greatly improved. Prof. Saussele highlights the ultimate goal of CML treatment currently as treatment-free remission, and raising the number of patients who can acheive this. This interview took place at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.

More from Susanne Saussele

1:10
The importance of better selecting patients with CML who are eligible for treatment discontinuation
Susanne Saussele • 22 Oct 2022
0:40
The impact of ACA in CML & the importance of monitoring these patients
Susanne Saussele • 22 Oct 2022
1:22
Examples of challenging scenarios for TFR in CML & how to manage them
Susanne Saussele • 22 Oct 2022
4:40
Antibody responses to COVID-19 vaccines in patients with hematological malignancies
Susanne Saussele • 11 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals